TY - JOUR
T1 - 2-hydroxyglutarate rides the cancer-immunity cycle
AU - Foskolou, Iosifina P.
AU - Bunse, Lukas
AU - van den Bossche, Jan
N1 - Funding Information: I.P.F. is supported by the HORIZON-MSCA grant with reference number 101107176 . Publisher Copyright: © 2023 The Author(s)
PY - 2023/10/1
Y1 - 2023/10/1
N2 - 2-hydroxyglutarate (2HG) is a biproduct of the Krebs cycle, which exists in a D- and L- enantiomer and is structurally similar to α-ketoglutarate. Both 2HG enantiomers have been described to accumulate in diverse cancer and immune cells and can influence cell fate and function. While D-2HG was originally considered as an ‘oncometabolite’ that aberrantly builds up in certain cancers, it is becoming clear that it also physiologically accumulates in immune cells and regulates immune function. Conversely, L-2HG is considered as an ‘immunometabolite’ due to its induction and regulatory function in T cells, but it can also be induced in certain cancers. Here, the authors review the effects of both 2HG enantiomers on immune cells within the tumor microenvironment.
AB - 2-hydroxyglutarate (2HG) is a biproduct of the Krebs cycle, which exists in a D- and L- enantiomer and is structurally similar to α-ketoglutarate. Both 2HG enantiomers have been described to accumulate in diverse cancer and immune cells and can influence cell fate and function. While D-2HG was originally considered as an ‘oncometabolite’ that aberrantly builds up in certain cancers, it is becoming clear that it also physiologically accumulates in immune cells and regulates immune function. Conversely, L-2HG is considered as an ‘immunometabolite’ due to its induction and regulatory function in T cells, but it can also be induced in certain cancers. Here, the authors review the effects of both 2HG enantiomers on immune cells within the tumor microenvironment.
UR - http://www.scopus.com/inward/record.url?scp=85166309931&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.copbio.2023.102976
DO - https://doi.org/10.1016/j.copbio.2023.102976
M3 - Review article
C2 - 37515937
SN - 0958-1669
VL - 83
JO - Current opinion in biotechnology
JF - Current opinion in biotechnology
M1 - 102976
ER -